Thursday – Basic Science Track B

Full Name(Required)
Enter your first and last names as you would like them to appear on your certificates.
Enter the email you used to register for TOXINS 2026.

Please evaluate the speakers

Topic and Speaker(s)
ExcellentGoodFairPoor
Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A
Atsushi Yamagata, PhD (Japan)
Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams
Janine Brunner, PhD (Belgium)
Retrograde transport and membrane translocation at the ER
Frederic Bard, PhD (Singapore)
Low-dose intestinal exposure to botulinum neurotoxins increases susceptibility to Salmonella and Shigella infection
Federico Fabris, PhD (Italy)
Pre-synaptic terminal proteins and nicotinic receptors are depleted from mouse parasympathetic ganglionic junctions paralysed with botulinum neurotoxin type A
Gary Lawrence, BSc, DIC, PhD (Ireland)
Crystal structure of the catalytic domain of BoNT/X in complex with its substrate, VAMP2
Sara Persson Kosenina, PhD (Sweden)
YesNo
Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A
Atsushi Yamagata, PhD (Japan)
Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams
Janine Brunner, PhD (Belgium)
Retrograde transport and membrane translocation at the ER
Frederic Bard, PhD (Singapore)
Low-dose intestinal exposure to botulinum neurotoxins increases susceptibility to Salmonella and Shigella infection
Federico Fabris, PhD (Italy)
Pre-synaptic terminal proteins and nicotinic receptors are depleted from mouse parasympathetic ganglionic junctions paralysed with botulinum neurotoxin type A
Gary Lawrence, BSc, DIC, PhD (Ireland)
Crystal structure of the catalytic domain of BoNT/X in complex with its substrate, VAMP2
Sara Persson Kosenina, PhD (Sweden)
YesNo
Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A
Atsushi Yamagata, PhD (Japan)
Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams
Janine Brunner, PhD (Belgium)
Retrograde transport and membrane translocation at the ER
Frederic Bard, PhD (Singapore)
Low-dose intestinal exposure to botulinum neurotoxins increases susceptibility to Salmonella and Shigella infection
Federico Fabris, PhD (Italy)
Pre-synaptic terminal proteins and nicotinic receptors are depleted from mouse parasympathetic ganglionic junctions paralysed with botulinum neurotoxin type A
Gary Lawrence, BSc, DIC, PhD (Ireland)
Crystal structure of the catalytic domain of BoNT/X in complex with its substrate, VAMP2
Sara Persson Kosenina, PhD (Sweden)
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care

Scam Warning

Due to scam emails being sent, please note that INA will NOT email you to wire money to anyone on the Board of Directors or anyone else from the INA.

Join Our Mailing List

Click here to sign up, and then manage your subscription.